Company intelligence / Profile preview

ProRx

Chicago, Illinois, United States

Ownership: Private
Development stage: Other

Overview

ProRx is a biotechnology company focused on the development of proprietary pro-drug technologies designed to improve the safety and efficacy of existing therapeutic agents. The company's platform utilizes specific enzymatic triggers within the disease microenvironment to activate drugs locally, thereby reducing systemic toxicity and enhancing therapeutic index. ProRx is currently advancing a pipeline of candidates targeting oncology and inflammatory diseases, with a particular focus on galectin-3 inhibition and targeted protein delivery. By leveraging its expertise in medicinal chemistry and drug delivery, the company aims to transform standard-of-care treatments into more precise and tolerable therapies.

Therapeutic areas: GastroenterologyOtherOncology
Modalities: Small moleculeBiologicProtein
Industry: Biotech

Beyond the preview

Go deeper on ProRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProRx.

Explore the full profile